CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

Research output: Contribution to journalLetter

34 Scopus citations
Original languageEnglish (US)
Pages (from-to)2094-2096
Number of pages3
JournalLeukemia
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2013

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this